Kunngjøring av tildeling · 11.06.2025

Denmark, Iceland, Norway – Pharmaceutical products – Joint Nordic Procurement of Pharmaceuticals - 2025 - NF2.1302.a

SYKEHUSINNKJØP HF i København Ø publiserte denne kunngjøringen i TED 11.06.2025. Oppgitt verdi er 18 750 000 EUR. Kontrakten ble tildelt Accord Healthcare A/S, B. Braun Medical AS, Baxter A/S, Fresenius Kabi, Hameln Pharma ApS, Pfizer ApS, Sandoz A/S.

Type

Kunngjøring av tildeling

Publisert

11.06.2025

Oppdragsgiver

SYKEHUSINNKJØP HF

Sted

København Ø

Art

Varer

Verdi

18 750 000 EUR

CPV-koder

33600000

Leverandør (tildelt)

Accord Healthcare A/S, B. Braun Medical AS, Baxter A/S, Fresenius Kabi, Hameln Pharma ApS, Pfizer ApS, Sandoz A/S

TED-nummer

373008-2025

Beskrivelse

ATC Code: A04AA01, Generic Name: Ondansetron, Pharmaceutical form: Injection Fluid (ampule), Strength: 2 mg/ml, Pack size: 2 ml, Unit: 16 mg, Quantity in units: Denmark: 234.183, Iceland: 9.750. ATC Code: A04AA01, Generic Name: Ondansetron, Pharmaceutical form: Injection Fluid (ampule), Strength: 2 mg/ml, Pack size: 4 ml, Unit: 16 mg, Quantity in units: Denmark: 15.640, Iceland: 10.000. Each lot number is a separate lot for the pharmaceutical indicated and is put up for tender independently of the other lot numbers. This means that a tenderer may submit a tender for one, several or all lot numbers, and that framework agreements will be awarded separately for each lot number. However, the aim is to conclude framework agreements with different suppliers for the lot numbers 1 and 2, which are linked lot numbers. If there is only one compliant tender for either lot numbers 1 or 2, the framework agreement for the lot number in question is awarded to the supplier concerned. The supplier concerned will then be excluded from award on the other of the two lot numbers, and the framework agreement will be awarded to the supplier of the remaining suppliers offering the “best price-quality ratio”. If there are several compliant tenders for both lot numbers 1 and 2, the award under lot number 1 will take precedence. This means that if the same supplier has submitted a tender offering the “best price-quality ratio” for both lot numbers 1 and 2, and there are several compliant tenders for both lot numbers 1 and 2, the Contracting Authorities will only award the supplier concerned a framework agreement for lot number 1, since the framework agreement for lot number 2 is awarded to the supplier with the “second best price-quality ratio” under the lot number concerned. If there is only one compliant tender for both lot numbers 1 and 2, the framework agreements will be awarded to the suppliers of the respective compliant tenders, notwithstanding that this may mean that the same supplier will be awarded a framework agreement for both lot numbers 1 and 2. Under the title "Quantity in units", an estimated consumption of the pharmaceuticals is indicated for each of the countries. It should be noted that this estimate corresponds to the historical consumption of the pharmaceuticals put up for tender and that suppliers must expect that the actual purchase under a framework agreement may deviate significantly from the estimate. Reference is made to paragraph 5.6 of the tender specifications and clause 4.2 in the framework agreement.

Les hele kunngjøringen og konkurransegrunnlaget hos TED · Om oppdragsgiveren (org.nr. 916879067)

Andre kunngjøringer fra SYKEHUSINNKJØP HF

Kilde: TED – Tenders Electronic Daily, Den europeiske unions publikasjonskontor (© EU, gjenbruk tillatt med kildehenvisning). Viser kunngjøringer som er sendt til TED (over EØS-terskelverdiene); mindre anskaffelser finnes på doffin.no. Vi er ikke oppdragsgiver og tar ikke imot tilbud.